GlassScriptPhysician profile
Hayde Bolanos
NPI 1588059711
$7,892.68
in general payments reported to CMS, 2019-2025
30 companies · $3,317 in 2025
The $3,317 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $730 · 2022: $706 · 2023: $1,355 · 2024: $1,783 · 2025: $3,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,345 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,344.52 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $923.30 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Mannkind Corporation | $879.13 | 2021-2024 | Afrezza, V-Go |
| Otsuka America Pharmaceutical, INC. | $848.33 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Novo Nordisk INC | $845.29 | 2021-2025 | Ozempic, Rybelsus |
| Alkermes, INC. | $606.28 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Amgen INC. | $478.10 | 2021-2025 | Evenity, Repatha, Prolia |
| Axsome Therapeutics, INC. | $430.40 | 2024-2025 | Auvelity |
| Madrigal Pharmaceuticals | $393.44 | 2024-2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $389.36 | 2024-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $280.71 | 2024-2025 | Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $244.56 | 2022-2023 | Lokelma |
| E.R. Squibb & Sons, L.L.C. | $166.95 | 2025 | Cobenfy |
| Abbott Laboratories | $158.42 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $152.10 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $146.57 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $125.73 | 2025 | Indigo System |
| Corcept Therapeutics | $124.99 | 2025 | Korlym |
| Gilead Sciences, INC. | $124.98 | 2023 | Epclusa |
| Neurocrine Biosciences, INC. | $120.57 | 2024-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $117.55 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.56 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $70.44 | 2021-2022 | |
| Validus Pharmaceuticals LLC | $29.60 | 2025 | Raldesy, Equetro |
| Amarin Pharma, INC. | $28.86 | 2021 | |
| Supernus Pharmaceuticals, INC. | $23.12 | 2025 | Qelbree |
| Exact Sciences Corporation | $22.47 | 2023 | Cologuard Collection Kit |
| Biocryst US Sales Co., LLC | $15.20 | 2023 | Orladeyo |
| Dexcom, INC. | $15.00 | 2022 | |
| Vanda Pharmaceuticals INC. | $13.91 | 2025 | Hetlioz, Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.76 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayde Bolanos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.